Teva Pharmaceutical Statistics and Facts
Teva Pharmaceutical, a global generic drug manufacturer, is based in Israel. It has over 3,500 products that are marketed in more than 60 countries. Teva’s revenue comes mainly from generic prescription drugs. However, Teva also develops and markets its specialty and biopharmaceutical brands, primarily in Europe and the U.S. One-fifth of its total revenue is generated by its branded portfolio. It includes patented therapies that target central nervous system conditions (Austedo/Ajovy, Copaxone), cancer (Bendeka/Treanda), as well as respiratory conditions (ProAir and Qvar). Global competition has made it easier to commodify small-molecule generic drugs. However, Teva’s portfolio rationalization has led to less price erosion than peers.
Teva Pharmaceutical Industries Ltd. Major Costs:
- $584 million in long-lived asset impairments, primarily $424 million in identifiable intangible assets and tangible asset impairments in Europe and North America segments.
- $584 million in long-lived asset impairments, primarily $424 million in identifiable intangible assets and tangible asset impairments in Europe and North America segments.
- Amortization of $802 million in purchased intangible assets, of which $702 million is included in the cost of goods sold, and the remaining $99 million is included in Sales & Marketing expenses.
- $717 million in legal settlements and loss contingencies.
- $133 million in restructuring costs.
- A $7 million contingent consideration expense was incurred.
- $128 million in financial expenses, primarily related to the revaluation of marketable securities.
- $118 million in equity compensation costs.
- $23 million in costs for regulatory actions taken in facilities.
- $133 million in restructuring costs.
- Purchase of $15 million in R&D in progress.
- Minority interest adjustment of $15 million, with a $360 million tax effect.
Research and Development Expenses:
- GAAP expenses in 2021 for R&D were US$ 967 million.
- Non-GAAP expenses in 2021 for R&D were US$ 933 million.
- Comparatively, in 2020 expenses decreased due to a decrease in the pain and neuropsychiatry therapeutic areas, partially offset by higher R&D expenses related to generic products, including biosimilar.
2022 Business Outlook
- Revenues are expected to be $15,600 – $16,200 million
- Non-GAAP diluted earnings per share are expected to be $2,40 – $2.60
- Free cash flow is expected to be $1,900 – $2,200 million
Statistics
Teva Pharmaceutical Industries’ Revenue 2012-2021 (in a Million U.S. Dollars)
Teva Pharmaceutical Industries is the largest global generic drug manufacturer. The company had total revenue of approximately 15.9 billion U.S. Dollars in 2021. This is the Teva Pharmaceutical Company’s revenue for the years 2012-2021.
Teva Pharmaceutical Industries’ Net Income 2012-2021 (in a Million U.S. Dollars)
This graph shows the net income for pharmaceutical company Teva between 2012 and 2021. Teva Pharmaceutical is the largest global generic drug manufacturer. The company reported approx. 417 million US$ net profit in 2021. This was Teva’s first year of positive income after 4 years of losses.
Teva Pharmaceutical Industries Revenue 2018-2021 By Region (in a Million U.S. Dollars)
This table shows the revenue of Teva Pharmaceutical Industries from 2018 to 2021. It is sorted by region. Teva Pharmaceutical is the largest global generic drug manufacturer. The company’s European revenues reached approximately 4.9 billion U.S. Dollars in 2021.
Teva Pharmaceutical’s Number of Employees 2018-2021 By Region
This stat shows the number and location of employees at pharmaceutical company Teva between 2018 and 2021. Teva Pharmaceutical is the largest global generic drug manufacturer. Teva Europe employed 18,122 people in 2021.
Teva: Expenditure on Research and Development 2012-2021
This graph shows Teva’s research and development spending from 2012 to 2021. Teva Pharmaceutical is the largest global generic drug manufacturer. The company spent nearly one billion dollars in research and development in 2021.
Teva Pharmaceutical Industries’ Specialty Medicines Revenues Breakdown 2018-2021
This statistic shows how specialty medicine revenues of pharmaceutical company Teva have been broken down by product from 2018 to 2021. Teva Pharmaceutical Industries is the world’s largest generic drug manufacturer. Copaxone, the top-selling drug in the world, generated revenue of approximately one billion dollars in 2021.
Recent Developments:
The year 2022
- Contracts/Agreements; In March, Teva Pharmaceuticals agreed with the Attorney General of Rhode Island that settles the state’s and its subdivision’s opioid-related claims.
In the year 2021
- Asset Disposal; In February, Teva announced the sale of its O.T.C. brand portfolio to Karo Pharma for EUR84 million.
- New Products/Services; In April, the company announced the launch of its 1000 mg strength generic version of Casana1 suppository medicine used to treat adults with active ulcerative proctitis in the U.S.
- New Products/Services; In April, the company announced the launch of its generic version of AZOPT 1% to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma.
- New Products/Services; In May, Teva Pharmaceutical Industries Ltd. affiliate, Teva Pharmaceuticals, launched its generic Erythromycin tablets to treat bacterial infections.
- New Products/Services; In June, Teva announced the first generic PERFOROMIST, a formoterol fumarate inhalation solution to treat bronchoconstriction in patients with chronic obstructive pulmonary disease.
- Contracts/Agreements; In June, Teva Pharmaceutical Industries and Bioeq AG entered into a strategic partnership to commercially exclusively Bioeq’s FYB201.
- Contracts/Agreements; In October, Teva Pharmaceutical and MODAG GmbH entered into a collaboration to license and develop MODAG’s lead compound anle138b and a related compound, sery433.
The year 2020
- Contracts/Agreements; In January, the company won a defense logistics agency contract worth US$189.69 million, for the supply of Adenovirus Vaccine Type 4 and Type 7, for five years.
- Contracts/Agreements; In March, Teva Pharmaceuticals U.S.A., a U.S. company affiliate, and Celltrion Healthcare partnered to distribute HERZUMA 1 (trastuzumab-pkrb) for injection, a biosimilar to HERCEPTIN 1, in the U.S.
- Contracts/Agreements; In May, the company’s affiliate, Teva Pharmaceuticals U.S.A., Inc, entered into a partnership with Celltrion Healthcare to launch TRUXIMA in the U.S. to treat rheumatoid arthritis.
- Divestiture; In July, a business joint venture of Teva Pharmaceutical and Takeda Pharmaceutical agreed to divest the majority of its generic and operational assets to Nichi-Iko Pharmaceutical.
- Contracts/Agreements; In August, Teva Pharmaceutical and Alvotech entered into a strategic partnership with five commercially biosimilar product candidates in the U.S.
- New Products/Services; In October, the company’s subsidiary, Teva Canada, announced the availability of Aermony RespiClick, a device to treat bronchial asthma.
- Contracts/Agreements; In October, Teva Pharmaceutical’s affiliate, Teva Respiratory, entered into a partnership with Onica and Amazon Web Services to build and host its digital health platform.
- Contracts/Agreements; In November, Teva Pharmaceutical’s subsidiary, Abic Marketing Ltd., agreed with Prestige Biopharma to commercialize Prestige Biopharma’s Trastuzumab biosimilar in Israel.
